6.0 Pretreatment Evaluation 
6.1 History and physical examination, including documentation of all 
measurable disease. 
6.2 Height, weight, and performance status. 
6.3 Screening profile, BUN, and creatinine. 
6.4 CBC, differential, and platelet count. 
6 . 5 EKG 
6.6 Chest X-ray and CT scans of the chest and abdomen. 
6.7 Magnetic Resonance Image or CT scan of the brain. 
6.8 Additional CT scans as indicated to evaluate disease 
6.9 HLA typing. 
6.10 Anergy Battery: 7-antigen skin testing with control using the Merieux 
Tine Test will be placed and read 40 to 54 hours after placement. 
6.11 Skin Test: 10 7 washed and irradiated (5000 rads) UISO-MEL-4-IL-2 cells 
will be administered intradermally and the resultant induration at 40 to 54 
hours will be measured. 
6.12 Peripheral blood will be obtained for immune assay. These will be 
delivered to the laboratories of Dr. Cohen (Room 717, MSB; extension 6-9479) . 
6.12.1 Two (2) 10 cc Vaccutainer tubes without additive 
("Tiger" top or Red top) will be obtained for pretreatment serum. 
6.12.2 Four (4) 10 cc Vaccutainer tubes containing heparin 
(Green top) or 40 cc of heparinized blood will be obtained for lymphocyte 
proliferation assays. 
7.0 Immunization Plan 
7.1 Patients will receive at least four courses of immunization. The first 
six patients will receive a low number of injected cells. The subsequent six 
will receive the higher number. The immunizations will consist of irradiated 
(5000 rads) IL-2-secreting melanoma cells expressing defined MHC Class I- 
determinants . 
Low Dose: 5 x 10® intramuscular (IM) and 2 x 10 7 (x2) intradermal (ID) 
High Dose: 5 x 10 9 IM and 2 x 10 8 (x2) ID 
[354] 
Recombinant DNA Research, Volume 18 
